Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ropinirole
Drug ID BADD_D01966
Description Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole [A35711].
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.
Marketing Status Prescription; Discontinued
ATC Code N04BC04
DrugBank ID DB00268
KEGG ID D08489
MeSH ID C046649
PubChem ID 5095
TTD Drug ID D0R9EQ
NDC Product Code 43353-267; 55111-727; 43353-265; 0228-3660; 46708-262; 60429-822; 10135-677; 0228-3659; 68462-259; 0378-5505; 10135-676; 16729-238; 43353-258; 50090-4684; 55111-662; 50090-5167; 71335-1188; 71335-0064; 60429-818; 50090-4803; 10135-673; 68462-258; 43353-266; 68462-254; 46708-265; 71335-1231; 62332-109; 68462-257; 0228-3640; 0378-5502; 46708-264; 58032-1011; 0781-5786; 60429-821; 0378-5504; 16729-237; 10135-678; 70518-2439; 10135-679; 55111-659; 50090-2068; 71335-1982; 16729-233; 46708-266; 72189-222; 16729-232; 0378-5501; 0378-5503; 68462-253; 60429-817; 60429-823; 68462-255; 16729-235; 62332-108; 55111-661; 70518-2750; 60429-819; 55111-728; 0378-5525; 0781-5784; 0228-3658; 16729-234; 63629-8123; 10135-674; 10135-675; 68462-256; 61919-780; 0378-5550; 62332-110; 60429-820; 71335-1167; 62332-107; 0228-3661; 16729-236; 46708-263; 0781-5780; 0781-5788; 62332-111; 0781-5782
Synonyms ropinirole | 4-(2-(di-n-propylamino)ethyl)-2(3H)-indolone | ropinirol | SK&F 101468 | SKF 101468 | SK&F-101,468 | Requip | ropinirole hydrochloride
Chemical Information
Molecular Formula C16H24N2O
CAS Registry Number 91374-21-9
SMILES CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaplastic thyroid cancer05.02.05.006; 16.24.03.003--Not Available
Aneurysm24.02.01.001--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angina unstable24.04.04.004; 02.02.02.004--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anorectal disorder07.03.01.001--Not Available
Anxiety19.06.02.0020.001281%
Apathy19.04.04.0020.000854%Not Available
Aphasia19.21.01.001; 17.02.03.0010.000640%
Appendicitis11.01.07.001; 07.19.01.001--
Arrhythmia02.03.02.0010.000111%Not Available
Arteriosclerosis24.04.02.001--Not Available
Arteritis24.05.01.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.0010.001707%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Ataxia08.01.02.004; 17.02.02.001--
Atrial fibrillation02.03.03.0020.001067%
Atrioventricular block02.03.01.002--Not Available
Aura17.02.07.011--Not Available
Azotaemia20.01.01.001--Not Available
Back pain15.03.04.0050.000640%
Balanoposthitis21.09.03.001--Not Available
Basal cell carcinoma23.08.02.001; 16.03.02.001--Not Available
Benign intracranial hypertension17.07.02.001--Not Available
Biliary colic09.02.01.001--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 25 Pages